Drugs / Ultibro
last change Jan 2025 re-read 2 minutes ago

Ultibro

Other / unclassified

Developed for
chronic obstructive pulmonary disease
Investigated by
Hywel Dda Health Board · Swansea University · University Hospital, Bordeaux

Trials 2 · a red edge is where a trial was stopped

2017201820192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 41 trial
Phase 4 NCT02813200 Jan 2017 → Feb 2019 chronic obstructive pulmonary disease University Hospital, Bordeaux Completed No outcome recorded
Phase not applicable1 trial
NCT03527927 May 2017 → Aug 2019 chronic obstructive pulmonary disease Hywel Dda Health Board Completed No outcome recorded
Also used as a comparator or background therapy in 2 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 31 trial
Phase 3 NCT02579850 Comparator May 2015 → Jul 2017 chronic obstructive pulmonary disease Chiesi Farmaceutici S.p.A. Completed No outcome recorded
Phase 41 trial
Phase 4 NCT06282861 Comparator Feb 2024 → Jan 2025 chronic obstructive pulmonary disease Fundacio Privada Mon Clinic Barcelona Terminated No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as Ultibro “The participants will choose: Ultibro® (Breezhaler device) or Duaklir® (Genuair device) or Anoro® (Ellipta device) or Spiolto® (Respimat device) and they will be prescribed the...” NCT03527927
3

NCT02579850

NCT06282861

NCT02813200

Modality Other / unclassified “a single-inhaler dual bronchodilator combination of indacaterol plus glycopyrronium (IND/GLY)” PMID 29429593 Feb 2018
Route Inhaled “administered once daily via DPI” NCT02579850